DYN
Price
$8.37
Change
+$0.19 (+2.32%)
Updated
Jul 8, 04:59 PM (EDT)
Capitalization
1.19B
22 days until earnings call
TSBX
Price
$0.37
Change
-$0.00 (-0.00%)
Updated
Jul 8, 04:56 PM (EDT)
Capitalization
8.4M
36 days until earnings call
Interact to see
Advertisement

DYN vs TSBX

Header iconDYN vs TSBX Comparison
Open Charts DYN vs TSBXBanner chart's image
Dyne Therapeutics
Price$8.37
Change+$0.19 (+2.32%)
Volume$90.12K
Capitalization1.19B
Turnstone Biologics
Price$0.37
Change-$0.00 (-0.00%)
Volume$100
Capitalization8.4M
DYN vs TSBX Comparison Chart in %
Loading...
DYN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TSBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DYN vs. TSBX commentary
Jul 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DYN is a Hold and TSBX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 09, 2025
Stock price -- (DYN: $8.39 vs. TSBX: $0.36)
Brand notoriety: DYN and TSBX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DYN: 130% vs. TSBX: 24%
Market capitalization -- DYN: $1.19B vs. TSBX: $8.4M
DYN [@Biotechnology] is valued at $1.19B. TSBX’s [@Biotechnology] market capitalization is $8.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $309.49B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DYN’s FA Score shows that 1 FA rating(s) are green whileTSBX’s FA Score has 1 green FA rating(s).

  • DYN’s FA Score: 1 green, 4 red.
  • TSBX’s FA Score: 1 green, 4 red.
According to our system of comparison, both DYN and TSBX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DYN’s TA Score shows that 4 TA indicator(s) are bullish while TSBX’s TA Score has 7 bullish TA indicator(s).

  • DYN’s TA Score: 4 bullish, 5 bearish.
  • TSBX’s TA Score: 7 bullish, 2 bearish.
According to our system of comparison, TSBX is a better buy in the short-term than DYN.

Price Growth

DYN (@Biotechnology) experienced а -3.34% price change this week, while TSBX (@Biotechnology) price change was +3.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.39%. For the same industry, the average monthly price growth was +14.41%, and the average quarterly price growth was +12.94%.

Reported Earning Dates

DYN is expected to report earnings on Oct 30, 2025.

TSBX is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+9.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DYN($1.19B) has a higher market cap than TSBX($8.41M). TSBX YTD gains are higher at: -26.524 vs. DYN (-64.389). TSBX has higher annual earnings (EBITDA): -59.34M vs. DYN (-395.31M). DYN has more cash in the bank: 677M vs. TSBX (21.8M). TSBX has less debt than DYN: TSBX (690K) vs DYN (23.3M). DYN (0) and TSBX (0) have equivalent revenues.
DYNTSBXDYN / TSBX
Capitalization1.19B8.41M14,134%
EBITDA-395.31M-59.34M666%
Gain YTD-64.389-26.524243%
P/E RatioN/AN/A-
Revenue00-
Total Cash677M21.8M3,106%
Total Debt23.3M690K3,377%
TECHNICAL ANALYSIS
Technical Analysis
DYNTSBX
RSI
ODDS (%)
Bullish Trend 1 day ago
71%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 13 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
DYN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TSBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSSKX83.38N/A
N/A
Fidelity Stock Selec-Class K
DTSGX16.62N/A
N/A
Wilshire Small Company Growth Invmt
AWSAX16.88N/A
N/A
Invesco Global Core Equity A
CMGYX31.58N/A
N/A
Columbia Select Mid Cap Gro Fd I3
FTSAX37.42N/A
N/A
FullerThaler Behvrl S-M Cor Eq A

DYN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DYN has been loosely correlated with RNA. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if DYN jumps, then RNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYN
1D Price
Change %
DYN100%
+2.57%
RNA - DYN
56%
Loosely correlated
+1.56%
CRNX - DYN
55%
Loosely correlated
+1.07%
XNCR - DYN
52%
Loosely correlated
+4.16%
SYRE - DYN
51%
Loosely correlated
+2.03%
RVMD - DYN
50%
Loosely correlated
-0.63%
More

TSBX and

Correlation & Price change

A.I.dvisor tells us that TSBX and FBLG have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TSBX and FBLG's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TSBX
1D Price
Change %
TSBX100%
+0.91%
FBLG - TSBX
28%
Poorly correlated
-1.14%
CHRS - TSBX
26%
Poorly correlated
-7.88%
ARQT - TSBX
26%
Poorly correlated
-2.69%
FULC - TSBX
25%
Poorly correlated
+1.45%
NERV - TSBX
25%
Poorly correlated
-0.61%
More